News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering
News Ipsen takes on BMS as kidney cancer pill launches in EU Cabometyx could take market share from Opdivo
News NICE recommends funding for three thyroid cancer drugs Eisai's drug finally funded after two year delay
Partner Content Partner Content Hear from MedImmune and Ipsen at SMi’s Injectable Drug Deliv... Launch of Injectable Drug Delivery
News Ipsen aims for new liver cancer use of Cabometyx Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
Partner Content Partner Content Ipsen presents on oral peptides innovations, advances and de... Ipsen presents on oral peptides innovations & delivery
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
